0

Global Neuroblastoma Drugs Market 2019-2023

  • Published: Jan 2019
  • Pages: 118
  • SKU: IRTNTR30755
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The neuroblastoma drugs market size will grow by USD 190.82 million during 2019-2023. The report offers an analysis of the market based on product (chemotherapy, immunotherapy, and others). The neuroblastoma drugs market research report further presents in-depth insights into the growth prospects of the market across geographic regions such as Asia, Europe, North America, and ROW. The report analyzes the market’s competitive landscape and offers information on several companies including Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Teva Pharmaceutical, and United Therapeutics.

Below are some of the key findings from the neuroblastoma drugs market analysis:

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.

Get a FREE sample now!  

Global Neuroblastoma Drugs Industry Overview

Cancer research organizations are working extensively towards the identification of therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth. In case of patients suffering from neuroblastoma, a cell surface antigen, GD2 (O-acetyl-GD2 ganglioside), is observed to be overexpressed. This is encouraging researchers to come up with specific monoclonal antibodies against GD2. The growing demand for anti-GD2 antibodies is one of the critical reasons that will drive the neuroblastoma drugs market’s growth. An anti-GD2-specific monoclonal antibody called Dinutuximab was the first drug approved for the treatment of neuroblastoma. The increasing sales of anti-GD2 drugs are due to site-specific action of these drugs and they do not pose any cytotoxic effects in the body. Chemotherapy has harmful cytotoxic side effects which will impact the quality of life of neuroblastoma patients. Hence, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma. These factors are driving the growth of neuroblastoma drugs market during the forecast period.

The continual focus on identifying several new tumor targets through improved research of the etiology of neuroblastoma has resulted in the development of novel therapies for the treatment of relapsed refractory neuroblastoma. It is a fatal condition where a patient’s neuroblastoma returns or becomes unresponsive to the treatment. The study of new tumor targets enables the development of novel-antibodies and cell-mediated immunotherapy agents for the condition. This will drive the neuroblastoma drugs market to grow at a CAGR of over 4% during the forecast period. CUDC-904, Ch14.18, and 1311-MIBG are some of the novel therapies under research and development for neuroblastoma.

Top companies covered in the neuroblastoma drugs market research report

The neuroblastoma drugs market is moderately concentrated. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, the industry analysis report will allow clients to identify new growth opportunities and design innovative strategies to improve their share in the market.

The report offers a complete analysis of various companies including:

  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer
  • Teva Pharmaceutical
  • United Therapeutics

Neuroblastoma drugs market segmentation based on geographic regions

  • Asia
  • Europe
  • North America
  • ROW

North America will contribute to the highest market share throughout the forecast period. The increasing incidence of neuroblastoma, availability of reimbursement schemes and new drug approvals for the treatment of neuroblastoma are factors responsible for the high growth of the neuroblastoma drugs market in the region.

Neuroblastoma drugs market segmentation based on product

  • Chemotherapy
  • Immunotherapy
  • Others

The chemotherapy segment accounted for the highest market share in the neuroblastoma drugs market. This can be attributed to the inherent advantages of drugs which involve site-specific action. However, the market share of the segment is expected to decline in the forthcoming years due to the harmful cytotoxicity-related side-effects of chemotherapy.

Key highlights of the global neuroblastoma drugs market for the forecast years 2019-2023:

  • CAGR of the market during the forecast period 2019-2023
  • Detailed information on factors that will accelerate the growth of the neuroblastoma drugs market during the next five years
  • Precise estimation of the global neuroblastoma drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the industry across various geographies such as Asia, Europe, North America, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on several vendors
  • Comprehensive details on factors that will challenge the growth of the companies

 

We can help! Our analysts can customize the market research report to meet your requirements. Get in touch

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Immunotherapy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Improvements in research and development for treatment of relapsed
  • refractory neuroblastoma
  • Availability of improved diagnostic modalities
  • Rising number of patient support initiatives

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer
  • Teva Pharmaceutical
  • United Therapeutics

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Reports 2019
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>